NorthWest Biotherapeutics Inc (NWBO)

[Pyrrhonian]

Sales x 3 = $120/pps

Evaluate pharma ranks DCVax L as third on their orphan drugs list with $2.1B in sales potential for ND-GBM alone. Add in another $2B for recurrent GBM. Add is another $2B for all lesser gliomas. That's $6B. Then value Direct at a conservative $4B for three inoperable indications. That isn't all that far fetched at all and comes in at $10B in sales. That's a conservative $30B market cap, or $250/pps fully diluted.

It sounds crazy but saying JAZZ could be $180/pps when it was $1 was crazy too.